Tom DeWeerdt
Chief Financial Officer.
Your global network strategy points to 104 upcoming programs, 60% of them on parenteral platforms. Vials are the single largest primary container format by count, with syringe and cartridge volumes rising as high-growth formats and cold chain demand expected to double. Stable and progressive, we're always anticipating the future needs of our clients, and confirmed CMO capacity across the industry hasn't kept pace with growth like this.
$1B
1Billion invested in sterile fill finish & Drug-Device combination infrastructure
250
US device assembly capacity of 250 million units per year
400 p/m
New isolator vial and lyophilization line capable of producing batch sizes of up to 300,000 vials at 400 units per minute
That's precisely the gap PCI has spent the last several years closing with more than $1 billion invested in sterile fill-finish and drug-device combination infrastructure across the US and Europe, engineered for exactly the formats and volumes your pipeline demands. Rooted in experience, our industry-leading heritage engenders the trust to deliver the future legacy AstraZeneca is building.
Whichever combination of vials, prefilled syringes, cartridges and autoinjector or pen devices your products require, PCI brings unparalleled knowledge, know-how, and expertise across our global integrated network with the flexibility to shift format mix as your programs evolve from clinical to commercial scale.
High-speed, and lyophilized; engineered at true commercial scale.
From 2,000 to 300,000 syringes per batch
Device-agnostic assembly, engineered for the formats you use today and the ones you'll need tomorrow.
Our teams can support AstraZeneca with world-class CDMO solutions from development through commercialization and beyond with quality and safety built into every step of the product pathway.
As a premium CDMO, we hold ourselves to the highest standards, and we've made significant, sustained investments to strengthen delivery, quality, and reach across our integrated network. AstraZeneca’s strategy calls for regional manufacturing and packaging capability in both the EU and US for every launch. PCI's network is built exactly that way, with free trade zone capabilities and supply chain expertise that give your products regionally secure supply without sacrificing a single, unified quality standard.
new AVI systems will support more than 70 million prefilled syringes and cartridges, and 40 million vials, annually.
significant new investment in autoinjector and pen device assembly infrastructure, backed by device-agnostic tooling that adapts as technology evolves
foreign trade zone and customs warehousing support, plus Pre-IND program experience, from our experts in tariff mitigation
sterile fill-finish and device assembly footprints across North America and Europe, positioned where your launches need them
our sustainability program is independently benchmarked through EcoVadis and validated through the Science Based Targets initiative (SBTi), the same third-party frameworks that anchor AstraZeneca’s supplier sustainability program.
Chief Financial Officer.
Chief People and Sustainability Officer
Chief Compliance and Quality Officer
Chief Operating Officer
Chief Commercial Officer
Chief Corporate Development Officer
President, Development and Manufacturing Services